Metahexamide

Metahexamide
Names

IUPAC name 1-(3-amino-4-methylphenyl)sulfonyl-3-cyclohexylurea
Identifiers
CAS Number	565-33-3^Y
ChEMBL	ChEMBL507419^N
ChemSpider	10785^N
Jmol interactive 3D	Image
KEGG	D07117^N
PubChem	11259
UNII	T3U6F5D722^Y
InChI InChI=1S/C14H21N3O3S/c1-10-7-8-12(9-13(10)15)21(19,20)17-14(18)16-11-5-3-2-4-6-11/h7-9,11H,2-6,15H2,1H3,(H2,16,17,18)^N Key: XXYTXQGCRQLRHA-UHFFFAOYSA-N^N InChI=1/C14H21N3O3S/c1-10-7-8-12(9-13(10)15)21(19,20)17-14(18)16-11-5-3-2-4-6-11/h7-9,11H,2-6,15H2,1H3,(H2,16,17,18) Key: XXYTXQGCRQLRHA-UHFFFAOYAB
SMILES CC1=C(C=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2)N
Properties
Chemical formula	C₁₄H₂₁N₃O₃S
Molar mass	311.4 g/mol
Pharmacology
ATC code	A10BB10
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is ^YN ?)
Infobox references

Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It was first described in 1959.^[1]

References

↑ Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci 82 (2): 614–7. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.

Oral anti-diabetic drugs, insulins and insulin analogs, and other drugs used in diabetes (A10)

Insulin

Sensitizers

Biguanides	Metformin^# Buformin<sp>‡ Phenformin^‡

TZDs/"glitazones" (PPAR)	Ciglitazone^§ Darglitazone^§ Englitazone^§ Lobeglitazone Netoglitazone^§ Pioglitazone Rivoglitazone^† Rosiglitazone Troglitazone^‡

Dual PPAR agonists	Aleglitazar^† Muraglitazar^§ Saroglitazar Tesaglitazar^§

Secretagogues

K+ ATP

Sulfonylureas	1st generation: Acetohexamide Carbutamide Chlorpropamide Metahexamide Tolbutamide Tolazamide 2nd generation: Glibenclamide (Glyburide)^# Glibornuride Glipizide Gliquidone Glisoxepide Glyclopyramide Glimepiride Gliclazide

Meglitinides/"glinides"	Nateglinide Repaglinide Mitiglinide

GLP-1 agonists

DPP-4 inhibitors

GPR40 Free fatty acid receptor 1

Fasiglifam^†

Analogs/other insulins

fast-acting (Insulin lispro
Insulin aspart
Insulin glulisine)
short-acting (Regular insulin)
long-acting (Insulin glargine
Insulin detemir
NPH insulin)
ultra-long-acting (Insulin degludec^†)
inhalable Exubera^‡
Afrezza

Other

Aldose reductase inhibitors	Epalrestat Fidarestat^§ Ranirestat^† Tolrestat^‡ Zenarestat^§

Alpha-glucosidase inhibitors	Acarbose Miglitol Voglibose

Amylin analog	Pramlintide

Sodium glucose transporter (SGLT2) inhibitors	Canagliflozin Dapagliflozin Empagliflozin Remogliflozin^§ Sergliflozin^§ Tofogliflozin^†

Other	Benfluorex^‡ Bromocriptine

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Monday, November 30, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.